



PreveCeutical Medical Inc

July 11 2018

Preveceutical Medical updates investors on its soluble gel drug delivery R&D

Health sciences firm PreveCeutical Medical Inc (CSE:PREV) said preliminary findings on its custom soluble gel applicator are encouraging as it updated on its R&D (research and development) work.

The programme involves testing an array of cannabis strains to commercialise cannabinoid-based soluble gels.

READ: PreveCeutical Medical closes oversubscribed placing and brings in C\$6.54mIn

Conventional methods of nasal drug delivery, such as drops and sprays, fail to deliver therapeutics far enough into the nasal cavity and are rapidly removed by the body's cleaning mechanisms.

Preveceutical's soluble gel formulations aim to resolve this by providing a fast nose-to-brain delivery of a host of therapeutic agents, including cannabinoids.

The group is developing a custom soluble gel applicator and its research partner, The University of Queensland, has received several prototype soluble gel spray devices from the group's manufacturer.


Although evaluations are ongoing, the preliminary results are promising, said the company.

Preveceutical shares are unchanged at C\$0.065.

Price: C\$0.1

Market Cap: C\$38.56M

1 Year Share Price Graph



Share Information

Code: PREV

Listing: CSE

52 week	High	Low
	0.17p	0.03p

Sector: Pharma & Biotech

Website: <https://preveceutical.com>

Company Synopsis:

PreveCeutical Medical Inc is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

Author:

Giles Gwinnett

+44(0)1202770386

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.



You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.